The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2

T.C. Booth, M. Nathan, A.D. Waldman, A.-M. Quigley, A.H. Schapira, J. Buscombe

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


SUMMARY: The functional imaging technique most widely used in European clinics to differentiate a true parkinsonian syndrome from vascular parkinsonism, drug-induced changes, or essential tremor is dopamine-transporter SPECT. This technique commonly reports dopamine-transporter function, with decreasing striatal uptake demonstrating increasingly severe disease. The strength of dopamine-transporter SPECT is that nigrostriatal degeneration is observed in both clinically inconclusive parkinsonism and early, even premotor, disease. In this clinical review (Part 2), we present the dopamine-transporter SPECT findings in a variety of neurodegenerative diseases, including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies. The findings in vascular parkinsonism, drug-induced parkinsonism, and essential tremor are also described. It is hoped that this technique will be the forerunner of a range of routinely used, process-specific ligands that can identify early degenerative disease and subsequently guide disease-modifying interventions. CBDcorticobasal degenerationDaTdopamine transporters18Ffluorine 18IBF123I-(S)-5-iodo-7-N-(1-ethyl-2-pyrrolidinyl) methylcarboxamido-2,3-dihydrobenzofuranIBZM123I-S-(K)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-3-iodo-6-methoxybenzamide123I-FP-CIT123I-ioflupane (N-ω-fluoropropyl-β CIT)MSAmultiple system atrophyMSA-Ppatients with multiple system atrophy with predominant parkinsonismPSPprogressive supranuclear palsy
Original languageEnglish
Pages (from-to)236-244
Number of pages9
JournalAmerican Journal of Neuroradiology
Issue number2
Publication statusPublished - 2015


Dive into the research topics of 'The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2'. Together they form a unique fingerprint.

Cite this